Anna-Mary Young
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna-Mary Young has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alessio Cortellini
Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
69 shared publications - Alexandra Emilia Schlaak
13Department of Internal Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
69 shared publications - Antonio D'Alessio
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK
69 shared publications - Bertram Bengsch
Department of Internal Medicine, Medical Center - University of Freiburg, Freiburg, Germany
69 shared publications - Caroline Ward
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
69 shared publications - Charalampos-Vlasios Stikas
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
69 shared publications
Latest Publications
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S8. The Variant Allele Frequency (VAF) of specific mutations changes during the course of the treatment. For instance, the VAF of ARID1a increases at treatment failure in patients 025 and 022 (both responders, Panel A). Furthermore, within the same patient, the VAF of different mutations changes coherently with the course of the treatment, as showed for patient 022 (B) and 002 (C), where the VAF increases at treatment discontinuation. Abbreviation: EOT, end of treatment.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S8. The Variant Allele Frequency (VAF) of specific mutations changes during the course of the treatment. For instance, the VAF of ARID1a increases at treatment failure in patients 025 and 022 (both responders, Panel A). Furthermore, within the same patient, the VAF of different mutations changes coherently with the course of the treatment, as showed for patient 022 (B) and 002 (C), where the VAF increases at treatment discontinuation. Abbreviation: EOT, end of treatment.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 4. List of antibodies used for mass cytometry
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 4. List of antibodies used for mass cytometry
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 1. Inclusion and exclusion criteria.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 1. Inclusion and exclusion criteria.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S5. Mean scores of global health status (GHS)/quality of life (QoL) and functioning domains on EORTC QLQ-C30 questionnaire at baseline and at the end of treatment.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S5. Mean scores of global health status (GHS)/quality of life (QoL) and functioning domains on EORTC QLQ-C30 questionnaire at baseline and at the end of treatment.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 8. Baseline characteristics of patients included in the circulating tumour DNA analysis.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Table 8. Baseline characteristics of patients included in the circulating tumour DNA analysis.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S2. Custom-developed bioinformatic variant calling pipeline to identify somatic SNVs and indels
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S2. Custom-developed bioinformatic variant calling pipeline to identify somatic SNVs and indels
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Methods 2: Overview of Biomarker analysis.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S10. Bar graphs showing the absence of association between entropy and response prior to the start of pembrolizumab (A) and at the end of treatment (B). Abbreviations: ICI, immune checkpoint inhibitor; ns, not significant; EOT, end of treatment.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S10. Bar graphs showing the absence of association between entropy and response prior to the start of pembrolizumab (A) and at the end of treatment (B). Abbreviations: ICI, immune checkpoint inhibitor; ns, not significant; EOT, end of treatment.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S1. HCC-specific targeted mutation panel utilised for NGS and quality filters implemented for variant calling.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Supplementary Figure S1. HCC-specific targeted mutation panel utilised for NGS and quality filters implemented for variant calling.